A Phase 4 interventional study of Bivalirudin and Unfractionated heparin in Extracorporeal Membrane Oxygenation Complication, Pediatric ALL and Anticoagulants, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2023-01-31.
Sponsored by University of Texas Southwestern Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 169 open to participants now, 275 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 689th largest by enrollment of the 1,269 interventional ones that give a count, is one of 39 that started in 2018, is one of 10 in phase 4, and was the 1,177th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 472 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →169 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Wake Forest University Health Sciences · Sites in United States
Ages 18+
St. Jude Children's Research Hospital · Sites in United States
Ages 8+ · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States
Ages 1–25
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 95 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.
This study: 1 Day to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,545 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 653 · Phase 2 593 · Phase 3 107 · Phase 4 10
First in 1984; this study’s year is marked. 39 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 35 across the 1,269 interventional studies, 110 across the 154 observational. Of the 1,181 that completed or were terminated, 438 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 1,545 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
University of Texas Southwestern Medical Center has 2 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
96 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03020030Phase 3Dana-Farber Cancer InstituteTreatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | 2026-11-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04851717Phase 3Acacia Pharma LtdInvestigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | 2027-10 |
| NCT03104491Leland MethenyInotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
Add all 96 to your calendar (.ics) → With an account.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators will prospectively enroll 30 neonatal and pediatric ECMO patients at a single pediatric Level 1 trauma center. The patients will be randomized into two arms; one arm will receive unfractionated heparin and the other arm will receive bivalirudin. There will be 15 patients in each arm for a total of 30 patients.
Primary aim will be to compare the efficacy of bivalirudin to unfractionated heparin.
The investigators will prospectively enroll 30 neonatal and pediatric ECMO patients at a single pediatric Level 1 trauma center. The patients will be randomized into two arms; one arm will receive unfractionated heparin and the other arm will receive bivalirudin. There will be 15 patients in each arm for a total of 30 patients.
The investigators hypothesize that neonatal and pediatric ECMO patients receiving bivalirudin will spend more time at goal anticoagulation and will experience less hemorrhagic and thrombotic complications when compared to patients receiving unfractionated heparin. Primary aim will be to compare the efficacy of bivalirudin to unfractionated heparin. The investigators secondary aim will be to define the incidence of hemorrhagic and thrombotic complications in patients receiving bivalirudin during ECMO.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients randomized to this arm will undergo usual care using unfractionated heparin as the primary anticoagulant.
Drug: Unfractionated heparin
Patients randomized to this arm will receive anticoagulation with bivalirudin
Drug: Bivalirudin
Continuous infusion
Continuous infusion
Percentage of Time Spent at Goal Anticoagulation
Time frame: through study completion, an average of 1-2 weeks
Number of Participants With One or More Major Bleeding Events
Bleeding events will include drop in hemoglobin, surgical site bleeding, intracranial hemorrhage, fatal bleeding, extra surgical or unexpected surgical site bleeding
Time frame: through study completion, an average of 1-2 weeks
Number of Blood Products Transfused
Will include fresh frozen plasma (FFP), packed red blood cells (pRBCs), platelets and cryoprecipitate
Time frame: through study completion, an average of 1-2 weeks
| Milestone | Unfractionated Heparin Group | Bivalirudin Group |
|---|---|---|
| Started | 14 | 16 |
| Completed | 14 | 16 |
| Not completed | 0 | 0 |
| percentage of time | Unfractionated Heparin Group | Bivalirudin Group |
|---|---|---|
| Percentage of Time Spent at Goal Anticoagulation | 0.63 (0.5 to 0.82) | 0.49 (0.31 to 0.54) |
Bleeding events will include drop in hemoglobin, surgical site bleeding, intracranial hemorrhage, fatal bleeding, extra surgical or unexpected surgical site bleeding
| participants | Unfractionated Heparin Group | Bivalirudin Group |
|---|---|---|
| Number of Participants With One or More Major Bleeding Events | 7 | 7 |
Will include fresh frozen plasma (FFP), packed red blood cells (pRBCs), platelets and cryoprecipitate
| mls/kg/day | Unfractionated Heparin Group | Bivalirudin Group |
|---|---|---|
| pRBCs | 12.2 (5.52 to 14.46) | 6.29 (2.49 to 8.41) |
| Platelets | 13.58 (2.43 to 23.94) | 4.55 (0.55 to 11.51) |
| FFP | 0.16 (0 to 2.84) | 1.15 (0.24 to 2.79) |
| Cryoprecipitate | 0 (0 to 0.19) | 0.1 (0 to 1.14) |
Collected over From Baseline, daily until the end of study, an average of up to 0.1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Unfractionated Heparin Group | 2/14 (14.3%) | 7/14 (50%) | 0/14 (0%) |
| Bivalirudin Group | 3/16 (18.8%) | 7/16 (43.8%) | 0/16 (0%) |
| Event | Unfractionated Heparin Group | Bivalirudin Group |
|---|---|---|
| Major bleeding eventBlood and lymphatic system disorders | 7/14 | 7/16 |
| Age, Categorical(Participants) | Unfractionated Heparin Group | Bivalirudin Group | Total |
|---|---|---|---|
| <=18 years | 14 | 16 | 30 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Unfractionated Heparin Group | Bivalirudin Group | Total |
|---|---|---|---|
| Female | 7 | 11 | 18 |
| Male | 7 | 5 | 12 |
| Race and Ethnicity Not Collected(Participants) | Unfractionated Heparin Group | Bivalirudin Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Unfractionated Heparin Group | Bivalirudin Group | Total |
|---|---|---|---|
| United States | 14 | 16 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Mar 2018 to primary completion in Oct 2021, 42 months.
Results were first posted in Jan 2023, 1 year 3 months after primary completion.
Of 30 phase 4 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 123. This study's 42 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bivalirudin
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
University of Texas Southwestern Medical Center →